Epidemiology of hematopoietic cancers in north of Iran: results of Mazandaran population based cancer registry

Objective: Hematopoietic malignancies include leukemias, lymphomas, plasma cell tumors, myelodysplastic syndromes, and malignant mastocytosis. There are very rare population-based epidemiological studies in hematopoietic cancers in Iran. The aim of this study was to describe the epidemiology of hematopoietic cancers in the north of Iran. Patients and Methods: This longitudinal study was carried out on cancer incidence data of Mazandaran Population-based Cancer Registry (MazPCR), which is responsible for recording cancer cases in the population of all counties of Mazandaran province (except Babol, which is covered by the Babol University of Medical Science) in 2014. We used SPSS 16 (SPSS Inc., Chicago, IL, USA) for statistical analysis. Chi-Square test was used and p-values < than 0.05 were considered statistically significant. Results: The Age-Standardized incidence Rates (ASRs) of leukemia were 8.2 and 5.4 per 100,000 in men and women, respectively. The ASRs of lymphoma among men and women were 7.1 and 3.2 and the ASRs of multiple myeloma were 1.7 for men and 1.8 for women. The ASRs of lymphoma and multiple myeloma in urban areas were higher than rural, while the ASR of leukemia in rural areas was higher. Conclusions: The ASRs of leukemia and lymphoma were higher in males and the ASR of multiple myeloma was higher in females in this study. The ASRs of leukemia and Hodgkin’s lymphoma in the MazPCR coverage area were higher than estimated ASRs in the world and Iran, while ASRs of Non-Hodgkin’s lymphoma were lower than those estimated for the world and Iran

Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry

Background: We aimed to report, for the first time, the results of the Iranian National Population-based Cancer Registry (INPCR) for the year 2014. Methods: Total population of Iran in 2014 was 76,639,000. The INPCR covered 30 out of 31 provinces (98 of total population). It registered only cases diagnosed with malignant new primary tumors. The main sources for data collection included pathology center, hospitals as well as death registries. Quality assessment and analysis of data were performed by CanReg-5 software. Age standardized incidence rates (ASR) (per 100,000) were reported at national and subnational levels. Results: Overall, 112,131 new cancer cases were registered in INPCR in 2014, of which 60,469 (53.9) were male. The diagnosis of cancer was made by microscopic confirmation in 76,568 cases (68.28). The ASRs of all cancers were 177.44 and 141.18 in male and female, respectively. Cancers of the stomach (ASR = 21.24), prostate (18.41) and colorectum (16.57) were the most common cancers in men and the top three cancers in women were malignancies of breast (34.53), colorectum (11.86) and stomach (9.44). The ASR of cervix uteri cancer in women was 1.78. Our findings suggested high incidence of cancers of the esophagus, stomach and lung in North/ North West of Iran. Conclusion: Our results showed that Iran is a medium-risk area for incidence of cancers. We found differences in the most common cancers in Iran comparing to those reported for the World. Our results also suggested geographical diversifies in incidence rates of cancers in different subdivisions of Iran

Cancer in Iran 2008 to 2025: Recent incidence trends and short-term predictions of the future burden

Policymakers require estimates of the future number of cancer patients in order to allocate finite resources to cancer prevention, treatment and palliative care. We examine recent cancer incidence trends in Iran and present predicted incidence rates and new cases for the entire country for the year 2025. We developed a method for approximating population-based incidence from the pathology-based data series available nationally for the years 2008 to 2013, and augmented this with data from the Iranian National Population-based Cancer Registry (INPCR) for the years 2014 to 2016. We fitted time-linear age-period models to the recent incidence trends to quantify the future cancer incidence burden to the year 2025, delineating the contribution of changes due to risk and those due to demographic change. The number of new cancer cases is predicted to increase in Iran from 112 000 recorded cases in 2016 to an estimated 160 000 in 2025, a 42.6 increase, of which 13.9 and 28.7 were attributed to changes in risk and population structure, respectively. In terms of specific cancers, the greatest increases in cases are predicted for thyroid (113.8), prostate (66.7), female breast (63.0) and colorectal cancer (54.1). Breast, colorectal and stomach cancers were the most common cancers in Iran in 2016 and are predicted to remain the leading cancers nationally in 2025. The increasing trends in incidence of most common cancers in Iran reinforce the need for the tailored design and implementation of effective national cancer control programs across the country. © 2021 Union for International Cancer Control